Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

COVID-19 infections weighed on Merck & Co Inc's (NYSE: MRK) Q1 earnings, with several people avoiding visits to hospitals or even the doctor early in the first quarter. The company reported Q1 EPS of $1.40, which missed the analyst consensus estimate of $1.63 and was down around 7% Y/Y.

Merck Earnings Fall Short of Expectations As Sales Weakened By Widespread Infections

Merck's reported disappointing results, the latest in a string of drug companies that failed to clear the bar set by Wall Street.

Merck Earnings Fell Short of Expectations. Here's What Caused the Miss.

Shares of Merck & Co. Inc. dropped 3.4% in premarket trading Thursday, after the drug giant reported first-quarter profit and revenue that missed expectations, as the COVID-19 pandemic and loss of market exclusivity weighed on pharmaceutical sales. Net income slipped to $3.18 billion, or $1.25 a share, from $3.22 billion, or $1.26 a share, in the year-ago period.

Merck stock drops after adjusted profit surprisingly falls, revenue comes up short

Merck & Co Inc reported a 1.2% fall in quarterly profit on Thursday, hurt by a drop in visits to the doctor's office because of a resurgence in COVID-19 cases at the beginning of the year in the United States.

Merck quarterly profit falls on COVID-19 hit

KENILWORTH, N.J.--(BUSINESS WIRE)-- #earnings--Merck Announces First-Quarter 2021 Financial Results

Merck Announces First-Quarter 2021 Financial Results

Merck is scheduled to report its Q1 2021 results on Thursday, April 29. We expect the company to likely post revenue and earnings above the consensus estimates, led by continued expansion of Keytruda, and a recovery in the company's vaccines as well as the animal.

Earnings Beat In Cards For Merck's Q1?

AbbVie

Bristol-Myers

Gilead Sciences

GlaxoSmithKline

Johnson & Johnson

Novartis

So, which pharmaceutical stocks should be on your radar, if dividends are a top priority? Consider these seven compelling opportunities.

7 Pharmaceutical Stocks With Dividends in Hand

Merck KGaA (not to be confused with the U.S.-based Merck) saw its EPS increase by 50% in 2020. The company is guiding for another year of EBITDA growth in 2021.

Merck KGaA: Robust Growth Results, But The Stock Isn't Cheap

Amgen

AstraZeneca

Companies likely seeking bolt-on acquisitions, not mega-deals

Top Pharma Giants Expected to Be Most Active in M&A

Caterpillar

McDonald's

Altria

A quick glance at the calendar for this week shows some 900 publicly traded companies are scheduled to report March quarter earnings this week.

Earnings Previews: Altria, Caterpillar, McDonald's, Merck

As the number of Covid-19 infections explodes in India, drug companies have announced a number of efforts to get treatments to the country.

Merck and Gilead Sciences Sign Deals to Aid India's Covid-19 Fight

Merck & Co Inc (NYSE: MRK) has partnered with five Indian generic drugmakers to expand production and access to Molnupiravir, its experimental oral therapeutic for the treatment of COVID-19. A part of these non-exclusive voluntary licensing agreements includes Cipla Ltd, Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd (NYSE: RDY), Emcure Pharmaceuticals Limited, and Hetero Labs Limited.

Merck Teams Up With Five Indian Generic Players To Expand COVID-19 Drug Access, Production

Merck said Tuesday it has entered voluntary licensing agreements with five Indian generic drug makers to expand access to molnupiravir, an investigational oral antiviral agent currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19. "The scale of human suffering in India at this moment is devastating, and it is clear that more must be done to help alleviate it," Merck Chief Executive Kenneth C.

Merck in licensing deals with 5 Indian generic drug makers to expand access to COVID-19 therapry

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck to Hold Investor Briefing Featuring Organon on May 3

Merck to Hold Investor Briefing Featuring Organon on May 3

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck Announces Voluntary Licensing Agreements with Five Indian Generics Manufacturers to Accelerate and Expand Global Access to Molnupiravir

Amid Humanitarian Crisis in India, Merck Announces Voluntary Licensing Agreements with Five Indian Generics Manufacturers to Accelerate and Expand Global Access to Molnupiravir, an Investigational Oral Therapeutic for the Treatment of COVID-19

Its vaccine might not have panned out as expected, but Merck has more in the works.

This Pharma Giant Lost the Vaccine Race, But Its COVID-19 Journey May Not Be Over

Abbott Labs

Becton, Dickinson and Co.

Healthcare stocks have some excellent dividend stocks among their ranks, and these three names are among the most reliable to buy. The post 3 Top Blue-Chip Healthcare Stocks With Healthy Dividends appeared first on InvestorPlace.

3 Top Blue-Chip Healthcare Stocks With Healthy Dividends

BioNTech SE

Quest Diagnostics

Regeneron Pharmaceuticals

Teladoc

Universal Health Services

The stock market is at all-time highs, and the world is starting to reopen. But these healthcare stocks have more growth opportunities ahead.

7 Healthcare Stocks for a Reopening World

Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.

Merck (MRK) to Report Q1 Earnings: What's in the Cards?

Roche Holding AG

The Food and Drug Administration advisory committee plans to hold a three-day meeting this week to evaluate a type of quicker approval used primarily for immuno-oncology drugs that are thought to help address unmet treatment needs among people with cancer. The FDA's "accelerated approval" process requires drug makers to conduct what are called confirmatory trials to back up the limited data used to inform the initial regulatory ok.

FDA to discuss whether immuno-oncology drugs with 'accelerated' approval should remain on the market

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck Accelerates Climate Goals; Announces Carbon Neutrality in Operations by 2025

Merck Accelerates Climate Goals; Announces Carbon Neutrality in Operations by 2025

Bayer AG

Biogen

British American Tobacco

Imperial Brands PLC

Lockheed Martin

Philip Morris

Sanofi

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). e are only interested in those targets that are attractively valued in historical comparison.

Wide-Moat Stocks On Sale - The May 2021 Heat Map

Merck (MRK) will start evaluating oral molnupiravir in non-hospitalized COVID-19 patients in a late-stage study. It stops MK-7110 development due to requirement of additional studies.

Merck (MRK) Stops MK-7110 Development, Focuses on Molnupiravir

Shares of Merck & Co. were up 0.1% in premarket trading on Thursday after the drug company said the oral antiviral COVID-19 treatment it is developing with Ridgeback Therapeutics did not help hospitalized patients in a mid-stage clinical trial. The companies now plan to test molnupiravir in non-hospitalized COVID-19 patients in a Phase 3 trial, with plans to file for emergency authorization in the second half of the year.

Merck scraps two treatments for hospitalized COVID-19 patients, will focus on antiviral for non-hospitalized patients

Merck announced Thursday it will end the development of its experimental drug for patients hospitalized with severe Covid-19.

News for Merck Stock (MRK)